CoChat
Sign Up
Cited by 200Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 189 of the 190 references it cites were found in a registry or an index, and 1 are not checked yet.

Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier

Open access
Teleanu, Raluca Ioana, Preda, Manuela Daniela, Niculescu, Adelina-Gabriela, Vladâcenco, Oana, Radu, Crina Ioana, Grumezescu, Alexandru Mihai, Teleanu, Daniel Mihai·2022·Pharmaceutics
DOI 10.3390/pharmaceutics14050987PMC PMC9145636
Open this paper in CoChat — free accountOpen PDF

Abstract

The blood–brain barrier (BBB) has shown to be a significant obstacle to brain medication delivery. The BBB in a healthy brain is a diffusion barrier that prevents most substances from passing from the blood to the brain; only tiny molecules can pass across the BBB. The BBB is disturbed in specific pathological illnesses such as stroke, diabetes, seizures, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease. The goal of this study is to offer a general overview of current brain medication delivery techniques and associated topics from the last five years. It is anticipated that this review will stimulate readers to look into new ways to deliver medications to the brain. Following an introduction of the construction and function of the BBB in both healthy and pathological conditions, this review revisits certain contested questions, such as whether nanoparticles may cross the BBB on their own and if medications are selectively delivered to the brain by deliberately targeted nanoparticles. Current non-nanoparticle options are also discussed, including drug delivery via the permeable BBB under pathological circumstances and the use of non-invasive approaches to improve brain medication absorption.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14050987

Cites

189 of 190 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The blood–brain barrier elements. Reprinted from Ref. [14], MDPI, 2021.
Figure 1 The blood–brain barrier elements. Reprinted from Ref. [14], MDPI, 2021.CC BY · PubMed Central
Figure 2 Schematic illustration summarizing some of the major neurological disorders associated with impairment of the BBB. Reprinted from Ref. [25], MDPI, 2021.
Figure 2 Schematic illustration summarizing some of the major neurological disorders associated with impairment of the BBB. Reprinted from Ref. [25], MDPI, 2021.CC BY · PubMed Central
Figure 3 Schematic representation of cerebral capillary showing endothelial cell in (A) normal and (B) glioblastoma. Reprinted with permission from Ref. [32], Copyright 2020, Elsevier.
Figure 3 Schematic representation of cerebral capillary showing endothelial cell in (A) normal and (B) glioblastoma. Reprinted with permission from Ref. [32], Copyright 2020, Elsevier.CC BY · PubMed Central
Figure 4 Schematic representation of the MRI-guided FUS system used by Park et al. Reprinted from Ref. [138], PLOS, 2017.
Figure 4 Schematic representation of the MRI-guided FUS system used by Park et al. Reprinted from Ref. [138], PLOS, 2017.CC BY · PubMed Central
Figure 5 Schematic representation of dual-functionalized (Tf–Pen) liposomes translocation across the BBB, followed by endocytosis into glioblastoma cells. Reprinted with permission from Ref. [173], Copyright 2019, Elsevier.
Figure 5 Schematic representation of dual-functionalized (Tf–Pen) liposomes translocation across the BBB, followed by endocytosis into glioblastoma cells. Reprinted with permission from Ref. [173], Copyright 2019, Elsevier.CC BY · PubMed Central
Figure 6 Main BBB crossing pathways for nanosystems. Abbreviations: CNS–central nervous system; NCL–nanostructured lipid carriers; NPs–nanoparticles. Reprinted from Ref. [188], Dove Press Ltd., 2015.
Figure 6 Main BBB crossing pathways for nanosystems. Abbreviations: CNS–central nervous system; NCL–nanostructured lipid carriers; NPs–nanoparticles. Reprinted from Ref. [188], Dove Press Ltd., 2015.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 5

  1. (2021, December 03). Circulation and the Central Nervous System Anatomy and Physiology I. Available online: https://courses.lumenlearning.com/ap1/chapter/circulation-and-the-central-nervous-system/.
  2. Dhanda, 2005, Approaches for drug deposition in the human olfactory epithelium, Drug Deliv. Technol., 5, 64
  3. National Center for Biotechnology Information (2022, April 16). PubChem Patent Summary for WO-9107947-A1, Available online: https://pubchem.ncbi.nlm.nih.gov/patent/WO-9107947-A1.
  4. Article, 2016, Solid Lipid Nanoparticles—A Review, J. Crit. Rev., 3, 5
  5. Gao, H., and Gao, X. (2018). Brain Targeted Drug Delivery Systems: A Focus on Nanotechnology and Nanoparticulates, Elsevier Science.

Cited by

Sorted by citations

See all 200

Related

See all

Metadata

Authors
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M.
Affiliations
  • Carol Davila University of Medicine and Pharmacy (RO)
  • Universitatea Națională de Știință și Tehnologie Politehnica București (RO)
  • Bucharest Emergency University Hospital (RO)
  • University of Bucharest (RO)
Corresponding author
Grumezescu, Alexandru Mihai
ORCID
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-05-04
Volume
14
Issue
5
Pages
987
ISSN
1999-4923 (ISSN-L)
DOI
10.3390/pharmaceutics14050987
PMC
PMC9145636
OpenAlex
W4229057365
Cited by
200
References
189
Citations by year
2026: 33 · 2025: 72 · 2024: 57 · 2023: 26 · 2022: 12
FWCI
4.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
blood-brain barrier, brain drug delivery, nanoparticles, blood-brain barrier disruption, targeted drug delivery, non-invasive drug delivery, blood-brain barrier permeability, neurological disorders, Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review